US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

It is estimated that more than 5 million people worldwide suffer from ulcerative colitis, a chronic inflammation of the colon ...

Marc Perez, a Bayside local, is in need of a lifesaving kidney transplant from a living donor after being diagnosed with a ...

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

COVID-19 testing includes molecular (PCR), antigen (rapid), and antibody (serology) tests, each serving different ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease wit ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq ...